Trevena (NASDAQ:TRVN) will be announcing its earnings results before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02. On average, analysts expect Trevena to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
TRVN traded up $0.02 during trading on Thursday, hitting $0.95. The stock had a trading volume of 3,515 shares, compared to its average volume of 441,106. The stock has a market cap of $87.73 million, a P/E ratio of -2.31 and a beta of 2.34. Trevena has a twelve month low of $0.38 and a twelve month high of $3.58. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.18. The business’s 50 day simple moving average is $1.01.
Several brokerages have weighed in on TRVN. HC Wainwright set a $4.00 target price on shares of Trevena and gave the company a “buy” rating in a research note on Monday, June 24th. Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. Finally, ValuEngine downgraded shares of Trevena from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $5.38.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Recommended Story: Return on Investment (ROI)
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.